Sort   by:  
 Page size 
GenomicsEwing sarcoma tumors - RRBS - samples
RRBS data of 86 Ewing patients (French). Illumina HiSeq 2000/2500 (Fastq files available). Sheffield et al. Nat Med. 2017 Jan 30
EGAD00001003133 | EGA
GenomicsGenomic landscape of Ewing sarcoma (ICGC project)
The Ewing sarcoma project aims to sequence 100 complete genomes of cells of patients suffering from this disease. It is an initiative of great projection, since this is the second most common bone tumor in children and teenagers. The goal of the project is to establish the catalogue of somatic mutat...
EGAS00001000855 | EGA
GenomicsMethylation of Ewing sarcoma tumors (ICGC)
Ewing sarcoma (ES) is a primary bone tumor initiated by an EWSR1-ETS gene fusion. To characterize the methylation of Ewing sarcoma, reduced representation bisulfite sequencing was performed.
EGAS00001002161 | EGA
GenomicsTargeting the DNA Repair Pathway in Ewing Sarcoma
Ewing’s Sarcoma is a bone and soft tissue tumor that primarily affects adolescents and young adults. With current therapies, 70% of patients with localized disease survive but survival for metastatic and recurrent disease is poor. Whole genome sequencing of 19 Ewing’s Sarcoma tumors showed that STAG...
EGAS00001000839 | EGA
GenomicsEwing sarcoma - WGS - samples
Description not provided
EGAD00001001051 | EGA
GenomicsPCGP EWS WGS - samples
DATA FILES FOR SJEWS-WGS
EGAD00001001020 | EGA
GenomicsInstitut Curie Neuroblastoma data access Committee
Data Access Committee EGAC00001000319
EGAC00001000319 | EGA
GenomicsAMC Dept. Oncogenomics
Data Access Committee EGAC00001000321
EGAC00001000321 | EGA
Genomicsena-DATASET-AMC-11-05-2015-14:58:16:693-185 - samples
The majority of neuroblastoma patients have tumors that initially respond to chemotherapy, but a large proportion of patients will experience therapy-resistant relapses. The molecular basis of this aggressive phenotype is unknown. Whole genome sequencing of 23 paired diagnostic and relapsed neurobla...
EGAD00001001360 | EGA
GenomicsNeuroblastoma relapse trio series from the AMC
The majority of neuroblastoma patients have tumors that initially respond to chemotherapy, but a large proportion of patients will experience therapy-resistant relapses. The molecular basis of this aggressive phenotype is unknown. Whole genome sequencing of 23 paired diagnostic and relapsed neurobla...
EGAS00001001183 | EGA
Sort   by:  
 Page size